Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T13:35:46.217Z.
Calculation as of: 2026-10-06T13:35:46.217Z.
Quote observation: 2026-10-06T13:35:11.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b8a0cb47064437e8b9c77c3ec53eeb060705b9d611480c07f1c1fa4a72564033
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
bioAffinity Technologies, Inc.
Market Cap
$2.67M
EV/FCF Ratio
N/A
| NAME | MARKET CAP | EV/FCF RATIO |
|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | $2.67M | N/A |
| iSpecimen Inc. (ISPC)vs › | $2.68M | N/A |
| Jaguar Health, Inc. (JAGX)vs › | $2.74M | N/A |
| FibroBiologics, Inc. Common Stock (FBLG)vs › | $2.47M | N/A |
| iTonic Holdings Ltd. (ITOC)vs › | $2.38M | N/A |
| GeoVax Labs, Inc. (GOVX)vs › | $2.36M | N/A |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.32M | N/A |
| BioRestorative Therapies, Inc. (BRTX)vs › | $3.04M | N/A |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.12M | N/A |
| Aethlon Medical, Inc. (AEMD)vs › | $3.35M | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
